Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Seven Hills
mi
from
Henderson, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Seven Hills
mi
from
Henderson, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Oakey
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Oakey
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at MountainView
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at MountainView
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
The Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
The Preston Robert Tisch Brain Tumor Center
mi
from
Durham, NC
Click here to add this to my saved trials
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Phase I Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide (IGF-1R/AS ODN) in 32 Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Phase I Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide (IGF-1R/AS ODN) in 32 Patients With Newly Diagnosed Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
DC Migration Study for Newly-Diagnosed GBM
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
DC Migration Study for Newly-Diagnosed GBM
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Use of Fluorescein Dye for the Removal of Brain Tumors
Use of Fluorescein Dye for the Removal of Brain Tumors
Status: Enrolling
Updated:  12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Use of Fluorescein Dye for the Removal of Brain Tumors
Use of Fluorescein Dye for the Removal of Brain Tumors
Status: Enrolling
Updated: 12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
4π Radiotherapy for Recurrent Glioblastoma Multiforme: A Feasibility Trial
Status: Enrolling
Updated:  12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
4π Radiotherapy for Recurrent Glioblastoma Multiforme: A Feasibility Trial
Status: Enrolling
Updated: 12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Abrams Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Abrams Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated:  12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated: 12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Tyrosine Kinase Inhibitors (TKI) and Body Composition
Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Tyrosine Kinase Inhibitors (TKI) and Body Composition
Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Florida (McKnight Brain Institute)
mi
from
Gainesville, FL
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Florida (McKnight Brain Institute)
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
NorthShore University Health System
mi
from
Evanston, IL
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
JFK Medical Center Neuroscience Institute
mi
from
Edison, NJ
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
JFK Medical Center Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Baylor University Medical Center
mi
from
Dallas, TX
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston (UTHealth)
mi
from
Houston, TX
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston (UTHealth)
mi
from
Houston, TX
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
West Virginia University
mi
from
Morgantown, WV
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center at Hackensack University
mi
from
Hackensack, NJ
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center at Hackensack University
mi
from
Hackensack, NJ
Click here to add this to my saved trials